HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 07, July 2017 – Food Science & Technology       » Scientists Demonstrate RNAi as an Antiviral Immunity in Mammals       » Singaporeans' Pain Costs Economy USD 6.2 billion Each Year       » China Fights Academic Paper Fraud After Peer Review Scandal       » Human Heart Tissue Grown from Stem Cells Improves Drug Testing       » Bioengineered Human Livers Mimic Natural Development       » Does Consuming Low-Fat Dairy Increase the Risk of Parkinson's Disease?      
EYE ON CHINA
China’s Healthcare Reforms: Who Will Survive?
Shanghai, February 2017 – China’s healthcare market in 2014 was USD 350 million and is projected to surpass USD 1 trillion in 2020 with a Compound Annual Growth Rate (CAGR) of over 19%, showing great growth potential. However, the country’s rapidly aging population is expected to cause significant strain on government budget as healthcare costs continue to rise. To lessen the financial burden, the Chinese government has enforced a series of healthcare reforms aimed at reducing healthcare expenditure.

“China’s healthcare reforms: Who will survive?” is the latest white paper released by Solidiance to give business players an outline of the Chinese healthcare reforms as well as to assess possible impacts on pharmaceuticals, medical devices, and healthcare service providers in China. The key finding of the study suggests that healthcare service providers will gain the most opportunities out of these reforms.

Goal of China’s healthcare reforms

Future healthcare costs resulted by a rapidly aging population will put enormous stress on state budget. To ensure future sustainability and significantly reduce healthcare expenditure in the next 10 years, the government has decided to initiate several healthcare reforms. The ultimate goal of the reforms is to:

  • Establish a decentralized healthcare system by lowering the utilization of level 3 public hospitals through a hierarchical structure. Patients who are looking to get treatment in level 3 hospitals will not be permitted before seeing GP clinics and level 1/level 2 hospitals initially.
  • Boost the development of private facilities. In the coming years, private facilities would be specialized and fill the needs that the public healthcare hospitals currently do not accommodate i.e. post-op care and rehab.
  • Promote the use and future development of GP clinics that are underutilized today.

Impacts of reforms on healthcare players in China

Pharmaceutical industry in China accounts for 40% of total healthcare spending, meaning that this segment will feel the biggest impact of the government’s cost-cutting pressure. The two-invoice policy (fapiao invoicing) set to start in early 2017 will present significant challenges as price cuts will eliminate the mark-up charged by smaller tier 2 and tier 3 distributors, making it difficult to enter hospitals’ drug selection process.

Medical device manufacturers will also feel the same price cutting initiatives given to Pharma companies, although not as significant. The government is pursuing a policy of supporting local companies to strengthen technical capabilities in the high-end device sectors with the goal of ending the monopoly of foreign firms in large medical devices.

With the Chinese government aiming to establish a decentralized and hierarchical healthcare system in the few years, Healthcare service providers are expected to gain the most opportunities in the face of these reforms. Given the high utilization rate in large level 3 public hospitals, the reform pushes to encourage patients to go to General Practitioner’s or level 1/level 2 public hospitals before being referred to level 3 public hospitals.


Source: Solidiance

Click here for the complete issue.

NEWS CRUNCH  
news Nestlé Introduces their Singapore R&D Centre
news Vitafoods Asia Elevates 2017 Learning Programme
news The Seventh International Meeting on Synthetic Biology (SB 7.0)
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy